Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
Want to see IMDX full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.3Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents clear operational and regulatory progress (FDA submission engagement, ISO certification, registry momentum, pricing validation, TAM affirmation, emerging head-to-head data and organ expansion), balanced against near-term financial pressures (Q2 cash burn >$9M, very low near-term revenue ~$0.25M), commercialization constraints (instrument placement), and timing uncertainty in Europe and FDA review details. Management provided concrete targets for margins, cost structure, and runway management and expects cash burn to decline in the back half of the year. Overall, the call signals meaningful de-risking and commercialization preparation while acknowledging near-term financial drag.Company Guidance
FDA Submission and Strong Engagement
Submitted GraftAssureDx to the FDA in late March and reported high, productive engagement during the review process; company expects continued interaction and anticipates first U.S. orders later this year.
GALACTIC Registry Momentum
Registry interest increased to 34 U.S. transplant centers (up from 28 six weeks ago, a ~21.4% increase), progressing toward a 50-center goal; first clinical trial agreement signed, moving closer to first patient-in and revenue generation from enrollment.
Pricing Validation and Addressable Market
Conducted survey of 200+ U.S. purchasers supporting willingness to pay with expected ASP in the hundreds; management reaffirms a $2 billion total addressable market (TAM) estimate.
Strong Reimbursement Benchmark
Medicare reimburses GraftAssureCore at $2,753 per result, providing a clear reimbursement anchor for U.S. commercialization and pricing discussions.
Regulatory and Quality Certifications
Received TUV SUD ISO 13485 certification in February; targeting UK regulatory compliance under IVDD in coming months and planning IVDR submission in the EU soon thereafter.
Early International Commercial Proof Points
Research-use GraftAssureIQ bought by a Swiss transplant hospital and expected orders from Southeast Asia; at least one international center established coverage and reimbursement—early validation of market need and potential repeat customers.
Gross Margin and Cost Structure Targets
Long-term gross margin target of ~70%+; initial guidance: model ASP in the hundreds and cost of goods sold slightly under $100 per result, with a 10% revenue share to former IP holders (Chronix) noted as an early deduction.
Emerging Head-to-Head Data
Head-to-head comparisons with legacy dd-cfDNA technologies are emerging, which management identifies as the fastest path to clinical trust and adoption.
Organ-Agnostic Expansion Potential
GraftAssure technology is organ-agnostic; management progressing plans to expand into heart transplant testing with expectations of a simpler clinical path and a prospective 510(k) pathway.
Financial Guidance Consistency and Capital Position
Q1 results reported in line with prior guidance; capital raise in February provides runway to sustain elevated R&D spending through planned programs and commercialization activities.
IMDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IMDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $5.10 | $6.42 | +25.88% |
Mar 26, 2026 | $4.11 | $3.56 | -13.38% |
Nov 10, 2025 | $6.80 | $7.53 | +10.66% |
Aug 11, 2025 | $2.61 | $2.51 | -3.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Insight Molecular Diagnostics (IMDX) report earnings?
Insight Molecular Diagnostics (IMDX) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Insight Molecular Diagnostics (IMDX) earnings time?
Insight Molecular Diagnostics (IMDX) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMDX EPS forecast?
IMDX EPS forecast for the fiscal quarter 2026 (Q2) is -0.24.